Bora Pharmaceutical Laboratories Inc. (Zhunan), a division of Bora Pharmaceuticals has partnered with TaiRx, Inc., a premier Taiwan new drug development company, to manufacture a novel anticancer.
Bora establishes a lead position in Taiwan's CDMO sector.
Bora establishes a leadership position in Taiwan's CDMO sector and plans to expand into the global CDMO market
TAIWAN – Fast-growing contract development and manufacturing organization (CDMO) BORA Pharmaceuticals, has announced a planned investment of $10 million to expand its Oral Solid Dose capabilities.
Bora Pharmaceuticals, a leading full-service contract development and manufacturing organization (CDMO), has appointed Sally Langa as its new Global SVP Sales and Marketing to help drive the.
KYOWA Pharmaceutical Industry Co. Ltd., a premier Japanese pharmaceutical company, has contracted with Bora Pharmaceutical Laboratories Inc. (Zhunan), a division of Bora Pharmaceuticals for the.
Bora Pharmaceutical Services Inc., a division of Bora Pharmaceuticals, has announced that its Mississauga, Ontario contract manufacturing and packaging facility has successfully completed its first.
Bora Pharmaceutical Laboratories, a division of Bora Pharmaceuticals, has added roller compaction technology to its solid dose capability offerings at its Zhunan, Taiwan contract manufacturing and.
Bora Pharmaceuticals Co., Ltd announced today that the contract development and manufacturing organization (CDMO) has successfully completed the acquisition of GSK’s Mississauga, Ontario (Canada).
Bora Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO) which specialises in immediate and modified release tablets and capsules, along with serialised.
